Key developments in the field of genomics—the study of the complete DNA of an organism—may make it possible to customize drug therapies, detect diseases, and engineer enzymes for improved health care outcomes. It's no wonder, then, that biotech and pharmaceuticals companies are moving quickly to capitalize on breakthroughs in the space.
Despite positive signs from a technological standpoint, though, these industries remain highly risky for investors. This is a reason why those keen to build exposure to genomics companies may be safest doing so through broader access available via exchange-traded funds (ETFs). Even given the relatively narrow investment niche that genomics firms represent, there are still multiple options for ETFs exploring this theme. Some notable options below all provide investors diversification within the space to help moderate risk.
